News & Updates
Filter by Specialty:
Daratumumab-containing regimens safe, effective against multiple myeloma
21 Nov 2021
Adding daratumumab to backbone treatments against multiple myeloma (MM) yields high clinical efficacy and has an acceptable toxicity profile, a recent study has found. Such regimens are good treatment options for newly diagnosed (ND) and relapsed/refractory (RR) MM.
Daratumumab-containing regimens safe, effective against multiple myeloma
21 Nov 2021Beta-blocker withdrawal improves functional capacity in HFpEF
20 Nov 2021
Withdrawal of beta-blocker treatment has led to increased maximal functional capacity in patients with heart failure with preserved ejection fraction (HFpEF) and chronotropic incompetence, reports a recent study, noting how use of beta-blockers deserved re-evaluation.